Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
DiaMedica Therapeutics Q1 2026 Earnings Call - DM199 Stroke Trial Nears Interim Analysis, Preeclampsia Pipeline Expands Amid FDA Hurdles
DiaMedica Therapeutics reported a modest increase in cash burn as it advances DM199 across two major indications, with the ReMEDy2 stroke trial crossing the 70% enrollment threshold for its planned en...
- ReMEDy2 stroke trial enrollment surpassed 70% of the target required for the interim analysis, with site activations now spanning the U.S., Canada, U.K., and six additional European countries.
- DiaMedica plans to complete the interim analysis for the stroke program by the end of 2026, with a futility check preceding any potential enrollment expansion.
- Phase II data from the prior ReMEDy1 study showed a 19% absolute improvement in functional outcomes for patients with moderate stroke severity, alongside a 50% reduction in patient deaths.
- +7 more takeaways
ACM Research Q1 2026 Earnings Call - 34% Revenue Growth Driven by AI Packaging Boom and New Product Ramp
ACM Research delivered a strong start to 2026, posting Q1 revenue of $231 million, a 34% year-over-year increase, fueled by surging demand in electroplating (ECP) and advanced packaging. Gross margin ...
- Q1 2026 revenue reached $231.3 million, up 34.2% year-over-year, driven by explosive growth in electroplating (ECP) and advanced packaging segments.
- Gross margin expanded to 46.5%, beating the midpoint of the 42%-48% long-term target range, supported by favorable product mix and lower inventory provisions.
- Shipments surged 53.6% to $240.7 million, with approximately 15% representing catch-up deliveries from Q4 2025, indicating strong backlog momentum.
- +7 more takeaways
Galapagos NV Q1 2026 Earnings Call - Rebranding to Lakefront Biotherapeutics Amid Gilead Partnership and Gamgertamig Pivot
Galapagos NV is executing a full-scale transformation, rebranding to Lakefront Biotherapeutics and securing a landmark partnership with Gilead for the Ouro Medicines portfolio. The deal centers on gam...
- Galapagos NV is rebranding to Lakefront Biotherapeutics, effective May 8, 2026, marking a full strategic transformation with a new management team and board focused on disciplined capital allocation and pipeline reshaping.
- The company secured a binding agreement with Gilead for the Ouro Medicines portfolio, centering on gamgertamig, a BCMA/CD3 T-cell engager with multi-billion-dollar revenue potential in autoimmune diseases.
- Gamgertamig has demonstrated rapid, durable complete responses with minimal cytokine release syndrome across over 60 patients in five autoimmune indications, positioning it as a potential first-in-class therapy.
- +7 more takeaways
GigaCloud Technology Q1 2026 Earnings Call - Europe Scales, New Classic Integration Begins, and Margins Show Natural Hedge
GigaCloud Technology delivered a quarter of disciplined growth that defied a soft U.S. furniture market. Revenue surged 32% to $359 million while EPS jumped 53% to $1.04. The company’s marketplace mod...
- Revenue grew 32% year-over-year to $359 million, while EPS surged 53% to $1.04, proving the resilience of the SFR marketplace model.
- GMV rose 17% year-over-year to $1.7 billion, driven by a 25% increase in active buyers and a 19% rise in active third-party sellers.
- Europe emerged as a high-growth vector, with marketplace GMV jumping 83% quarter-over-quarter and three-party seller GMV exploding over 500% year-over-year.
- +7 more takeaways
Akebia Therapeutics Q1 2026 Earnings Call - Vafseo Revenue Surges 32% as Dialysis Adherence Shifts to Observed Dosing
Akebia Therapeutics reported a strong start to 2026 with Vafseo revenue jumping 32% to $15.8 million in Q1, driven by a 60% increase in patients on therapy and broader adoption across dialysis organiz...
- Vafseo Q1 2026 net product revenue reached $15.8 million, a 32% increase year-over-year and the highest quarterly revenue since launch.
- Patient count on Vafseo grew 60% quarter-over-quarter to nearly 7,500 patients at the end of Q1 2026.
- Prescriber base expanded by 28% to approximately 1,025 prescribers, with 30% coming from dialysis organizations outside U.S. Renal Care.
- +12 more takeaways
Pharming Group N.V. Q1 2026 Earnings Call - Joenja Accelerates as RUCONEST Navigates Competitive Shift
Pharming Group delivered mixed Q1 2026 results, with RUCONEST revenue declining 15% year-over-year due to expected inventory drawdowns and a strategic exit from non-U.S. markets. Despite the headwind,...
- RUCONEST revenue fell 15% year-over-year, primarily driven by an 8% expected inventory drawdown at specialty pharmacies and a 3% impact from the strategic exit from non-U.S. markets.
- Joenja revenues grew 34% year-over-year to $14.1 million globally, with U.S. patient counts increasing 25% and the fill rate holding at a robust 85%.
- Management reported that nine months into the launch of a new oral competitor, the overwhelming majority of RUCONEST patients have remained on therapy, with many high-burden patients returning after trialing alternatives.
- +9 more takeaways
Rockwell Medical Q1 2026 Earnings Call - Profitability on the Horizon With 2026 Guidance Raised
Rockwell Medical delivered Q1 2026 results that fell short of prior-year sales but beat management’s own expectations, driven by operational discipline and a strategic pivot toward higher-margin inter...
- Q1 2026 net sales of $17.3 million declined 8% year-over-year but exceeded management’s own expectations, tracking toward raised full-year guidance.
- Gross margin improved to 17% from 16% in Q1 2025, with sequential monthly gains in gross profit, adjusted EBITDA, and net income throughout the quarter.
- Management raised 2026 full-year guidance: net sales now projected at $70–$75 million, adjusted EBITDA at $1–$2 million, and positive operating cash flow.
- +7 more takeaways
22nd Century Group Inc Q1 2026 Earnings Call - VLN Rollout Gains Traction as Revenue Rises 16% Sequentially
22nd Century Group reported a 16.1% sequential revenue increase to $4.1 million in Q1 2026, driven by early distribution of its VLN cigarettes with two major U.S. retailers. The company is shifting fr...
- Revenue rose 16.1% sequentially to $4.1 million in Q1 2026, marking the first clear sign of top-line traction since the VLN launch.
- Gross loss narrowed to $0.6 million from $0.8 million in Q4 2025, signaling early margin improvement as product mix shifts toward branded VLN.
- Operating loss widened slightly to $3 million from $2.8 million, reflecting disciplined but growing investments in marketing and sales capacity.
- +9 more takeaways
Public Service Enterprise Group Q1 2026 Earnings Call - Strong Start Driven by Gas Volumes and Nuclear Reliability
Public Service Enterprise Group delivered a robust first quarter, posting non-GAAP operating earnings of $1.55 per share, well above the $1.43 per share reported a year ago. The utility side benefited...
- Q1 2026 non-GAAP operating earnings reached $1.55 per share, beating the $1.43 per share reported in Q1 2025, driven by strong utility performance and favorable power generation margins.
- Full-year 2026 non-GAAP operating earnings guidance remains unchanged at $4.28 to $4.40 per share, reflecting management's confidence in steady execution and cost control.
- PSEG Power's gas operations and capacity revenues successfully offset the absence of the zero-emission certificate program, which concluded in May 2025, stabilizing the power segment's contribution.
- +9 more takeaways
Tactile Medical Q1 2026 Earnings Call - Revenue Surges 23% as Prior Authorization Rollout Tests Operational Agility
Tactile Medical delivered a robust Q1 2026, with total revenue climbing 23% year-over-year to $75.3 million, driven by a 23% jump in lymphedema sales and a 22% rise in airway clearance revenue. Gross ...
- Total revenue reached $75.3 million in Q1 2026, up 23% year-over-year, with lymphedema revenue at $62.2 million (up 23%) and airway clearance revenue at $13 million (up 22%).
- Gross margins expanded 250 basis points to 76.5%, reflecting lower manufacturing costs, stronger collections, and a favorable product and payer mix.
- Adjusted EBITDA swung to a $3.7 million profit from a $0.3 million loss in the prior year period, with the margin expanding to 4.9% from -0.4%.
- +12 more takeaways